Immutep Advances LAG-3 Immunotherapy Trials
Company Announcements

Immutep Advances LAG-3 Immunotherapy Trials

Immutep (IMMP) has released an update.

Immutep Limited, a biotechnology firm specializing in LAG-3 immunotherapies, has made significant strides in its clinical trials, including a pivotal Phase III trial for non-small cell lung cancer in collaboration with MSD. The company reported positive clinical data across several studies, including treatments for head and neck squamous cell carcinoma and metastatic breast cancer, while also solidifying its financial position with an extended cash runway until the end of 2026.

For further insights into IMMP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskImmutep’s Growth and Advancements Boost Market Visibility
TheFlyImmutep reports Q1 cash receipts from custmers $20,000
TheFlyImmutep announces first-in-human phase I study of IMP761
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App